Dr. Srinadh Komanduri, MD, MS
Claim this profileNorthwestern Memorial Hospital
Studies Barrett's Esophagus
Studies Esophageal Cancer
3 reported clinical trials
8 drugs studied
Affiliated Hospitals
Clinical Trials Srinadh Komanduri, MD, MS is currently running
WATS3D vs Seattle Protocol
for Barrett's Esophagus
The purpose of this research study is to learn about the best approach to sample patients with known or suspected Barrett's esophagus (BE) by comparing the standard Seattle biopsy protocol to sampling using wide area transepithelial sampling (WATS3D). Barrett's esophagus is a common condition that is used to spot patients at increased risk of developing a type of cancer in the esophagus (swallowing tube) called esophageal adenocarcinoma. The 5-year survival rate is as low as 18% for patients who get esophageal adenocarcinoma, but the rate may be improved if the cancer is caught in its early stages. Barrett's esophagus can lead to dysplasia, or precancerous changes, which occurs when cells look abnormal but have not developed into cancer. If the abnormal cells increase from being slightly abnormal (low-grade dysplasia), to being very abnormal (high-grade dysplasia), the risk of developing cancer (esophageal adenocarcinoma) goes up. Therefore, catching dysplasia early is very important to prevent cancer. Endoscopic surveillance is a type of procedure where endoscopists run a tube with a light and a camera on the end of it down a patients throat and remove a small piece of tissue. The piece of tissue, called a biopsy, is about the size of the tip of a ball-point pen and is checked for abnormal cells and cancer cells. Patients are being asked to be in this research study because they have been diagnosed with BE or suspected to have BE, and will need an esophagogastroduodenoscopy (EGD). Patients with BE undergo sampling using the Seattle biopsy protocol during which samples are obtained from the BE in a four quadrant fashion every 2 cm along with target biopsies from any abnormal areas within the BE. Another sampling approach is WATS3D which utilizes brushings from the BE. While both of these procedures are widely accepted approaches to sampling patients with BE during endoscopy, there is not enough research to show if one is better than the other. Participants in this study will undergo sampling of the BE using both approaches (Seattle biopsy protocol and WATS-3D); the order of the techniques will be randomized. Up to 2700 participants will take part in this research. This is a multicenter study involving several academic, community and private hospitals around the country.
Recruiting1 award N/A
WATS-3D Tissue Sampling
for Barrett's Esophagus Detection
Esophageal cancer is a deadly disease that is becoming increasingly common in the United States. Barrett's esophagus (BE) is a pre-cancerous state that can develop into esophageal cancer, but is highly treatable. Progression of BE to esophageal cancer is still common due to missed diagnosis of Barrett's esophagus recurrence following treatment. Wide-Area Trans-Epithelial Sampling (WATS-3D) is a new technology that uses brush sampling to examine larger areas of the esophagus as compared to conventional biopsies. Preliminary studies show improved detection of cancerous changes in Barrett's esophagus surveillance. The investigators hope to see if the addition of WATS-3D increases the rate of detection of recurrent BE following treatment, which is of the utmost importance since it would allow for earlier re-treatment of disease and ultimately allow for prevention of progression to esophageal cancer.
Recruiting1 award N/A
More about Srinadh Komanduri, MD, MS
Clinical Trial Related1 year of experience running clinical trials · Led 3 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Srinadh Komanduri, MD, MS has experience with
- WATS-3D Tissue Sampling Following Forceps Biopsies
- WATS-3D Tissue Sampling Prior To Forceps Biopsies
- Chemotherapy
- Endoscopic Eradication Therapies (EET)
- Esophagectomy
- Radiation
Breakdown of trials Srinadh Komanduri, MD, MS has run
Barrett's Esophagus
Esophageal Cancer
Adenocarcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Srinadh Komanduri, MD, MS specialize in?
Srinadh Komanduri, MD, MS focuses on Barrett's Esophagus and Esophageal Cancer. In particular, much of their work with Barrett's Esophagus has involved treating patients, or patients who are undergoing treatment.
Is Srinadh Komanduri, MD, MS currently recruiting for clinical trials?
Yes, Srinadh Komanduri, MD, MS is currently recruiting for 2 clinical trials in Chicago Illinois. If you're interested in participating, you should apply.
Are there any treatments that Srinadh Komanduri, MD, MS has studied deeply?
Yes, Srinadh Komanduri, MD, MS has studied treatments such as WATS-3D tissue sampling following forceps biopsies, WATS-3D tissue sampling prior to forceps biopsies, Chemotherapy.
What is the best way to schedule an appointment with Srinadh Komanduri, MD, MS?
Apply for one of the trials that Srinadh Komanduri, MD, MS is conducting.
What is the office address of Srinadh Komanduri, MD, MS?
The office of Srinadh Komanduri, MD, MS is located at: Northwestern Memorial Hospital, Chicago, Illinois 60611 United States. This is the address for their practice at the Northwestern Memorial Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.